FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 若股份曾以超過一個每股價 ...

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Hai Ji Ya Medical (06078.HK) by 1.0894 million shares on December 30, 2025, marking a total net reduction of 4.2976 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Hai Ji Ya Medical on 11 occasions, resulting in a cumulative net reduction of 1.3302 million shares [1] - As of now, southbound funds hold 209 million shares of Hai Ji Ya Medical, which accounts for 33.74% of the company's total issued ordinary shares [1] Group 2 - The company, Hai Ji Ya Medical Holdings Limited, primarily provides medical services through two business segments [2] - The hospital business segment focuses on offering comprehensive diagnosis and treatment services for cancer, including multiple cancer medical services such as radiotherapy, chemotherapy, surgery, and targeted therapy [2] - The other business segment mainly engages in various other operations, with the company primarily operating in the domestic market [2]

Group 1 - The core point of the article is that Haijia Medical has been actively repurchasing its shares, with a total of 11 buybacks this year, amounting to 3.2734 million shares and a total expenditure of 42.2829 million HKD [2][3] - On December 30, the company repurchased 334,600 shares at a price range of 12.390 to 12.530 HKD, totaling 4.1648 million HKD, while the stock closed at 12.480 HKD, down 0.56% for the day [2] - Since December 29, the company has conducted buybacks for two consecutive days, repurchasing a total of 570,600 shares for a cumulative amount of 7.1624 million HKD, during which the stock price has decreased by 1.73% [2] Group 2 - The detailed buyback information shows that on December 29, 2025, the company repurchased 236,000 shares at a maximum price of 12.750 HKD and a minimum price of 12.540 HKD, totaling 2.9976 million HKD [3] - The buyback activities include various dates with different volumes and prices, indicating a strategic approach to managing share value [3] - The highest buyback price recorded this year was 14.140 HKD on January 2, 2025, while the lowest was 12.040 HKD on December 17, 2025 [3]

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 30, 2023, spending HKD 4.165 million to repurchase 335,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - Haijia Medical (06078) announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1: Buyback Details - The company will repurchase 236,000 shares at a total cost of HKD 2.9976 million [1] - The buyback price ranges from HKD 12.54 to HKD 12.75 per share [1]

智通财经APP讯，海吉亚医疗(06078)发布公告，于2025年12月29日该公司斥资299.76万港元回购23.6万 股，回购价格为每股12.54-12.75港元。 ...

格隆汇12月29日丨海吉亚医疗(06078.HK)公告，12月29日耗资299.76万港元回购23.6万股，每股回购价 12.54-12.75港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股 ...

Group 1 - The core event was the "Technology Empowerment · Capital Breakthrough" sharing session held by Gelonghui, where the annual list of outstanding companies was announced [1] - Haijia Medical (6078.HK) was awarded the "Annual Outstanding Healthcare Enterprise" in the Gelonghui "Golden G Award" selection, recognizing its excellence in the healthcare industry [1] - The award criteria included innovation capability, technological leadership, market influence, social value, and sustainable development ability, aimed at honoring companies with outstanding performance and contributions in China's healthcare sector [1]